Global Immunohistochemistry (IHC) Antibody Market Size By Type of Antibody, By End-User, By Application, By Geographic Scope And Forecast

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Immunohistochemistry (IHC) Antibody Market Size and Forecast

Immunohistochemistry (IHC) Antibody Market size was valued at USD 3.2 Billion in 2023 and is projected to reach USD 4.7 Billion by 2030, growing at a CAGR of 7.4 % during the forecasted period 2024 to 2030.

Global Immunohistochemistry (IHC) Antibody Market Drivers

The market drivers for the Immunohistochemistry (IHC) Antibody Market can be influenced by various factors. These may include

  • Growing Prevalence of Chronic infections IHC assays are needed more frequently to identify, categorise, and predict the outcomes of chronic illnesses such cancer, autoimmune disorders, and infectious infections. IHC antibody sales are increasing because antibodies are essential for identifying particular antigens linked to a number of disorders.
  •  Technological Developments in Diagnostic TechniquesThe sensitivity, specificity, and throughput of IHC tests are improved by technological developments in multiplex IHC, digital pathology, and automated staining platforms. Antibodies that have been refined for these cutting-edge methods provide precise and effective illness detection and research, driving industry expansion.
  •  Quick Development of Personalised MedicineMolecular biomarker identification is critical for patient classification, treatment selection, and ongoing monitoring as the personalised medicine paradigm shifts. Antibody-based IHC assays facilitate the identification and characterisation of particular biomarkers, enabling tailored treatment choices and stimulating the market for IHC antibody products.
  •  Growing Uses in Drug DevelopmentIn preclinical and clinical research, immunohistochemistry assays are frequently employed to evaluate the safety, pharmacodynamics, and efficacy of drugs. Researchers can assess target expression, localization, and modulation in tissue samples using antibodies employed in immunohistochemistry (IHC), which aids in the discovery of new drugs in a variety of therapeutic areas including immunology, neurology, and oncology.
  •  Growing acceptance of Companion DiagnosticsThe need for IHC tests and antibodies is driven by the growing acceptance of companion diagnostics, which use biomarker-based assays to identify patients likely to respond to particular medicines. Precision medicine approaches are facilitated by companion diagnostic tests that use IHC antibodies to choose relevant medicines and improve patient outcomes.
  •  Extension of Life Sciences Research The need for antibodies for fundamental research and experimental investigations is fueled by ongoing life sciences research in the fields of genomics, proteomics, and cell biology. IHC antibodies provide a broad range of research applications by allowing researchers to visualise and characterise tissue shape, cellular location, and patterns of protein expression.
  •  Investments in Biomarker Discovery and ValidationThe need for antibodies for IHC assays is driven by an increase in funds allocated by government agencies, pharmaceutical companies, and academic institutions to biomarker discovery and validation projects. In order to provide prospects for the IHC antibody market, these studies seek to identify novel biomarkers for disease diagnosis, prognosis, and therapeutic targeting.
  •  Stricter Regulatory Standards and Quality RequirementsThe need for high-quality antibodies validated for IHC applications is driven by regulatory authorities’ emphasis on assay standardisation, validation, and quality control. In order to comply with regulatory standards, antibody makers must invest in stringent quality assurance procedures, validation studies, and documentation, guaranteeing the accuracy and repeatability of IHC results.

Global Immunohistochemistry (IHC) Antibody Market Restraints

Several factors can act as restraints or challenges for the Immunohistochemistry (IHC) Antibody Market. These may include

  • High Antibody CostAntibodies that have been validated for particular targets or applications, in particular, can be costly when employed in IHC tests. Antibody prices can be prohibitive, particularly for research labs and medical facilities with tight budgets, which would restrict the market’s ability to expand.
  •  Concerns about Antibody Specificity and ReproducibilityTo guarantee correct and dependable results in IHC experiments, antibody specificity and reproducibility are essential components. But worries about cross-reactivity, antibody quality, and batch-to-batch variability could make researchers and physicians less confident in IHC data, which would hinder the market’s expansion.
  •  Difficulties in Antibody Validation and StandardisationTo guarantee the dependability and uniformity of IHC assays among various platforms and laboratories, antibody validation and standardisation are crucial. However, obtaining consistent performance is difficult due to a lack of reference materials, quality control procedures, and standardised protocols for antibody validation, which limits market expansion.
  •  Restricted Access to High-Quality AntibodiesAlthough there are many antibodies available on the market for IHC applications, not all of them meet the necessary standards for specificity, sensitivity, and performance. The scarcity of high-quality antibodies that have been validated for IHC may limit the options available to researchers and physicians, which could hinder the uptake of IHC tests, especially for unusual or rare targets.
  •  Complexity of IHC Assay OptimisationAntigen retrieval techniques, staining procedures, antibody dilutions, and detecting systems are only a few of the parameters that go into optimising IHC assays. Researchers and labs may face difficulties due to the intricacy of assay optimisation and the requirement for technical know-how, which could lead to less-than-ideal assay performance and a delayed uptake of IHC techniques.
  •  Alternative Technologies and TechniquesIn addition to immunohistochemistry (IHC), alternative technologies and techniques such as digital pathology, in situ hybridization (ISH), and immunofluorescence (IF) provide additional or alternative methods for identifying and interpreting tissue biomarkers. The availability of these substitute techniques might draw focus and funding away from IHC assays, which would restrict market expansion.
  •  Regulatory and Ethical IssuesThe use of human tissue samples in IHC tests raises ethical, legal, and privacy issues that may make it difficult to enter and spread the market. IHC investigations become more sophisticated and expensive in order to comply with rules controlling the use of human materials, patient permission, and data protection, which may limit market expansion.
  •  Effects of the COVID-19 PandemicResearch initiatives, clinical trials, and diagnostic testing have all been delayed as a result of the pandemic’s disruption of laboratory operations, research activities, and healthcare services globally. The pandemic’s effects on the economy and resource shortages could discourage investment in IHC assays and antibody research, temporarily impeding market expansion.

Global Immunohistochemistry (IHC) Antibody Market Segmentation Analysis

The Global Immunohistochemistry (IHC) Antibody Market is Segmented on the basis of Type of Antibody, End-User, Application, And Geography.

By Type of Antibody

  • Monoclonal AntibodiesDeveloped from a single B-cell clone, monoclonal antibodies have excellent consistency and specificity, which makes them perfect for IHC applications.
  • Polyclonal AntibodiesThese antibodies can show broader reactivity and are made from several B-cell clones. They are useful for identifying several epitopes in IHC tests.
  • Primary AntibodiesSecondary antibodies coupled to reporter molecules are used to identify primary antibodies by their direct binding to target antigens in tissue samples.

By End-User

  • Hospitals and Diagnostic Labs IHC assays are used in hospitals and diagnostic labs for pathology services, patient management, and clinical diagnosis.
  • Pharmaceutical and Biotechnology businesses IHC assays are used by pharmaceutical and biotechnology businesses for preclinical research, drug development, and biomarker discovery.
  • Academic and Research Institutions IHC techniques are employed by academic and research institutions for translational studies, disease modelling, and basic research.

By Application

  • Cancer Diagnosis and PrognosisBy identifying certain biomarkers linked to tumour cells, antibodies utilised in IHC assays are essential in the diagnosis and prognostication of different forms of cancer.
  • Diseases That Are Infectious DiagnosisBy locating pathogens or antigenic markers in tissue samples, IHC antibodies are used to diagnose infectious illnesses.
  • Autoimmune Disease Diagnosis By identifying autoantibodies or immune cell infiltration in tissues, immunohistochemical techniques that use antibodies aid in the diagnosis of autoimmune illnesses.

By Geography

  • North America With the United States and Canada included, this region is a major market for IHC antibodies since it is home to some of the world’s top pharmaceutical businesses, academic research centres, and medical facilities.
  • Europe Europe, which includes nations like Germany, France, and the UK, is a significant market for IHC antibodies because to rising research expenditures, the incidence of chronic illnesses, and improvements in the region’s healthcare system.
  • Asia Pacific This area, which includes nations like China, Japan, and India, is seeing a sharp increase in the IHC antibody market as a result of growing research efforts, rising healthcare expenditures, and an expanding biotechnology industry.

Key Players

The major players in the Immunohistochemistry (IHC) Antibody Market are

  • Abcam plc
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Merck KGaA (EMD Millipore)
  • PerkinElmer, Inc.
  • Santa Cruz Biotechnology, Inc.
  • BioGenex Laboratories, Inc.

Report Scope

REPORT ATTRIBUTESDETAILS
STUDY PERIOD

2020-2030

BASE YEAR

2023

FORECAST PERIOD

2024-2030

HISTORICAL PERIOD

2020-2022

UNIT

Value (USD Billion)

KEY COMPANIES PROFILED

Abcam plc, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA (EMD Millipore), PerkinElmer, Inc., Santa Cruz Biotechnology, Inc., BioGenex Laboratories, Inc.

SEGMENTS COVERED

Type of Antibody, End-User, Application,Geography

CUSTOMIZATION SCOPE

Free report customization (equivalent up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We'll take a close look at the market using both numbers (quantitative) and less tangible things like consumer behavior (qualitative), breaking it down by different groups based on economic and other factors. You'll get market values in USD Billion for each of these segments and their sub-segments. We'll also point out which region and segment we think will grow the fastest and be the biggest overall. Expect a geographic breakdown, showing where the product/service is being used most and the things influencing the market in each area. The report covers the competitive scene, including rankings of the big players, their latest service/product launches, partnerships, expansions, and acquisitions over the last five years. We offer detailed company profiles, featuring an overview, insights, product comparisons, and SWOT analysis for the major companies. Get our take on the current and future market, considering recent events, growth opportunities, and the challenges and restraints in both new and established markets. We'll also dive deep with a Porter's Five Forces analysis to give you different angles on the market. Plus, we'll provide value chain insights and paint a picture of the market's dynamics, outlining growth opportunities in the future. And to top it off, you'll get 6 months of analyst support after your purchase!

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.

Related Reports

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email